[A24-63] Selpercatinib (solid tumours) - Benefit assessment according to § 35a Social Code Book V
Last updated 15.08.2024
Project no.:
A24-63
Commission:
Commission awarded on 15.05.2024 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Adults with advanced rearranged during transfection (RET) fusion-positive solid tumours, when treatment options not targeting RET provide limited clinical benefit, or have been exhausted
Added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
https://doi.org/10.60584/A24-63_en
| Project no. | Title | Status |
|---|---|---|
| A21-29 | Selpercatinib (RET fusion-positive thyroid cancer) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A21-28 | Selpercatinib (RET mutant medullary thyroid cancer) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A21-27 | Selpercatinib (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A22-65 | Selpercatinib (advanced NSCLC with RET fusion) – Benefit assessment according to § 35a SGB V | Commission completed |
| A22-106 | Selpercatinib (thyroid cancer) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| A24-62 | Selpercatinib (thyroid cancer) - Benefit assessment according to § 35a Social Code Book V | Commission completed |